Literature DB >> 7833276

Increased levels of soluble CD8 and CD4 in patients with infectious mononucleosis.

A Yoneyama1, K Nakahara, M Higashihara, K Kurokawa.   

Abstract

Plasma levels of soluble CD8 (sCD8) and soluble CD4 (sCD4) in 44 patients with infectious mononucleosis (IM) were studied. A marked increase in sCD8 (22366 +/- 2702 U/ml; control: 219 +/- 10 U/ml; P < 0.0001) and significant increase in sCD4 (19.3 +/- 0.9; control: 8.1 +/- 0.2, P < 0.0001) strongly suggest activation of both CD8+ and CD4+ lymphocytes, which is important in restraining Epstein-Barr virus-infected B lymphocytes. Levels of sCD8 strongly correlated with the percentage and the absolute number of both CD8+ and CD8(+)-HLA-DR+ lymphocytes. In addition, we showed increased release of sCD8 from lymphocytes in vitro and increased ratio between plasma sCD8 and the number of CD8+ lymphocytes in blood, indicating that elevation of plasma sCD8 is due to expansion of CD8+ subset as well as increased sCD8 release from each CD8+ cell. Increased sCD4 release from CD4+ lymphocytes, the number of which is not increased in the blood during IM, was also seen. Patients with more severe fever had higher levels of sCD8 and sCD4. During convalescence sCD8 and sCD4 levels showed progressive decrease; however, even at 60-119 d after onset the levels of sCD8 and sCD4 remained higher than normal, suggesting prolonged lymphocyte activation. These results suggest that sCD8 and sCD4 are useful in monitoring immune activation during IM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7833276     DOI: 10.1111/j.1365-2141.1995.tb08912.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Lower concentration of serum soluble CD8 in severe Hashimoto's disease.

Authors:  N Yamamoto; M Watanabe; F Matsuzuka; A Miyauchi; Y Iwatani
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

2.  Activation of myeloid cell-specific adhesion class G protein-coupled receptor EMR2 via ligation-induced translocation and interaction of receptor subunits in lipid raft microdomains.

Authors:  Yi-Shu Huang; Nien-Yi Chiang; Ching-Hsun Hu; Cheng-Chih Hsiao; Kai-Fong Cheng; Wen-Pin Tsai; Simon Yona; Martin Stacey; Siamon Gordon; Gin-Wen Chang; Hsi-Hsien Lin
Journal:  Mol Cell Biol       Date:  2012-02-06       Impact factor: 4.272

3.  Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Authors:  Adriana A Byrnes; David M Harris; Sowsan F Atabani; Beulah P Sabundayo; Susan J Langan; Joseph B Margolick; Christopher L Karp
Journal:  J Leukoc Biol       Date:  2008-09-19       Impact factor: 4.962

4.  Impaired delayed-type hypersensitivity response in mutant mice secreting soluble CD4 without expression of membrane-bound CD4.

Authors:  C R Wang; A Hino; T Yoshimoto; H Nagase; T Kato; K Hirokawa; A Matsuzawa; H Nariuchi
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

5.  Virus-associated apoptosis of blood neutrophils as a risk factor for invasive meningococcal disease.

Authors:  Harry Smith; Sharon L Rogers; Helen V Smith; David Gillis; Victor Siskind; Judith A Smith
Journal:  J Clin Pathol       Date:  2013-06-25       Impact factor: 3.411

6.  Lost in Translation: Lack of CD4 Expression due to a Novel Genetic Defect.

Authors:  Andrea Lisco; Peying Ye; Chun-Shu Wong; Luxin Pei; Amy P Hsu; Emily M Mace; Jordan S Orange; Silvia Lucena Lage; Addison Jon Ward; Stephen A Migueles; Mark Connors; Megan V Anderson; Clarisa M Buckner; Susan Moir; Adam Rupert; Alina Dulau-Florea; Princess Ogbogu; Dylan Timberlake; Luigi D Notarangelo; Stefania Pittaluga; Roshini S Abraham; Irini Sereti
Journal:  J Infect Dis       Date:  2021-02-24       Impact factor: 5.226

7.  Increased soluble CD4 in serum of rheumatoid arthritis patients is generated by matrix metalloproteinase (MMP)-like proteinases.

Authors:  Wen-Yi Tseng; Yi-Shu Huang; Nien-Yi Chiang; Yeh-Pin Chou; Yeong-Jian Jan Wu; Shue-Fen Luo; Chang-Fu Kuo; Ko-Ming Lin; Hsi-Hsien Lin
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.